Allogene Therapeutics’ (ALLO) Buy Rating Reaffirmed at HC Wainwright
MarketBeatHC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research report on Wednesday.
HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research report on Wednesday.